DPx Holdings Appoints Tyler D. Gronbach as Vice President of Communications

Report this content

DPx Holdings B.V. (DPx), owners of pharmaceutical services provider Patheon, DPx Fine Chemicals and Banner Life Sciences, today announced the appointment of Tyler Gronbach as vice president of communications. Gronbach will report to Rebecca Holland New, chief human resources officer and senior vice president of communications for DPx Holdings and will be based at the company’s headquarters in Durham, N.C.

In this new role, Gronbach will be responsible for developing and executing a fully integrated global communications strategy that will build greater awareness and support for the company’s strategy, solutions and thought leadership efforts with customers, news media, investors, opinion leaders and employees. He will also serve as the company’s primary liaison with the media.

“We are pleased to have Tyler join the organization. He has a strong record of leadership and results throughout his career and has successfully directed programs supporting complex marketing and communications challenges during periods of rapid growth, as well as during business transformations,” said Holland New. “Tyler will play a critical role in helping us communicate the strong value proposition our businesses deliver to the marketplace today and seeking new ways to help us tell our story with external and internal audiences.”

Gronbach most recently served as the senior vice president, corporate communications for Education Management Corporation, a leading provider of private post-secondary education, headquartered in Pittsburgh, Pa. In this role, he was responsible for developing internal and external communications strategies and advised senior leaders on investor relations, corporate marketing/branding, government affairs and other business matters.

“The company has successfully completed a major transformation and assembled a solid set of capabilities that uniquely positions them as a global provider of solutions to the pharmaceutical sector,” said Gronbach.  “This is a very exciting time to join the organization as we look to increase engagement with our stakeholders.” 

Prior to joining Education Management, Gronbach held the position of senior vice president, marketing & communications at Dex One Corporation, where he was responsible for developing the overall integrated communications strategy and objectives for the company. In addition, as a member of the senior leadership team at Dex One, he helped drive digital sales growth in excess of 30 percent in 2012 and repositioned the brand from a yellow pages publisher to a digital marketing services leader.

Prior to his role at Dex One, Gronbach served in a number of roles of increasing responsibility, including vice president, corporate communications at Qwest Communications International Inc., a Fortune 500 telecommunications carrier. He also served in leadership positions with other telecom and public relations agencies.

He holds a Bachelor of Arts degree in communications from Marist College.

DPx Media Relations

Tel: (919) 210-0986

Email: media@dpxholdings.com

About DPx Holdings B.V.
DPx Holdings B.V. is parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company offers customers unsurpassed quality, end-to-end solutions and value through its three business units. DPx Holdings is a leading provider of CDMO services, pharmaceutical products and other formulated products for various industries. The company was formed in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned by JLL Partners and Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. For more information, visit www.patheon.com/DPx.

About Patheon®
Patheon® is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, including small molecule API and biologic drug substances. Patheon, a business unit of DPx Holdings B.V., encompasses the combined commercial manufacturing capabilities and pharmaceutical product development services, as well as offers a full array of biologic services and pharmaceutical active pharmaceutical ingredients (API) development. Patheon is #1 in product development services, #2 in commercial scale product manufacturing and is #1 in quality. For more information, visit http://www.patheon.com.